Latest Genomic Health Inc. Stories
Complete Results from Positive Clinical Validation Study to be Presented at 2013 American Urological Association (AUA) Annual Meeting REDWOOD CITY, Calif., April 3, 2013 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that the clinical trial results validating its biopsy-based Oncotype DX® prostate cancer test will be presented by investigators from the University of California, San Francisco (UCSF) in an oral session at the American Urological Association...
New Findings Emphasize Oncotype DX's Real-life Impact for Patients and Physicians and Reduction in Healthcare Costs, Underscore Value of Broader Access for All Patients REDWOOD CITY, Calif. and ST. GALLEN, Switzerland, March 15, 2013 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced the presentation of results from 22 studies at the 13(th) St. Gallen International Breast Cancer Conference highlighting the impact of the Oncotype DX® breast cancer test around the...
Findings suggest value of Oncotype DX in tailoring radiation therapy treatment for select node-positive patients treated with hormonal therapy and chemotherapy REDWOOD CITY, Calif., March 13, 2013 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced positive results of a large study that demonstrates the Oncotype DX® Recurrence Score® result to be a robust predictor of loco-regional recurrence (LRR) in node-positive (N+), estrogen receptor (ER) positive patients...
Results Presented at the 14th Annual Advances in Genome Biology and Technology Meeting Reveal Novel Method for RNA-Sequencing and Mutation Identification REDWOOD CITY, Calif., Feb. 25, 2013 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced the results of two studies demonstrating that DNA strand-of-origin information can help further refine the identification of prognostic biomarkers, and that tumor specific gene mutations can be effectively examined using...
REDWOOD CITY, Calif., Feb. 6, 2013 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today reported financial results and business progress for the quarter and year ended December 31, 2012. Total revenue for the fourth quarter of 2012 increased to $60.4 million, compared with $53.4 million in the fourth quarter of 2011. Product revenue was $60.0 million in the fourth quarter of 2012, compared with $53.2 million for the fourth quarter of 2011, an increase of 13 percent....
REDWOOD CITY, Calif., Jan. 23, 2013 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced results from three studies of the Oncotype DX(®) Colon Cancer test at the 2013 Gastrointestinal (GI) Cancers Symposium, including new data demonstrating that Recurrence Score(®) (RS) results changed treatment recommendations in 45 percent of the enrolled stage II colon cancer patients. Presentations also include positive findings from a second health economics analysis...
REDWOOD CITY, Calif., Dec. 21, 2012 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that Kim Popovits, Genomic Health's Chairman, Chief Executive Officer, and President will present at the 31(st) Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 7 at 1:30 p.m. Pacific Time (PT). To access the live and subsequently archived webcast of the presentation, visit the Investor Relations section of Genomic Health's website at...
REDWOOD CITY, Calif., Dec. 10, 2012 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced the results from six studies of the Oncotype® DX breast cancer test presented at the 34(th) Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) reinforcing the impact of the test on facilitating better informed treatment decisions in patients with node-negative and node-positive invasive early-stage breast cancer. Additionally, two studies demonstrated the test's cost...
REDWOOD CITY, Calif., Nov. 28, 2012 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that the company will present results from six Oncotype® DX breast cancer test studies at the 34(th) Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS), taking place December 6-8, 2012 at the Henry B. Gonzalez Convention Center. Presentations include results from evaluations of the Oncotype DX breast cancer test's clinical utility and health economic value in various...
REDWOOD CITY, Calif., Nov. 9, 2012 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that Kim Popovits, Genomic Health's Chief Executive Officer, Chairman and President will present at the following conferences in November: Credit Suisse 2012 Healthcare Conference on Thursday, November 15, 2012 at 2:00 p.m. Mountain Time (MT) in Phoenix, Arizona; and 24th Annual Piper Jaffray Healthcare Conference on Tuesday, November 27 at 2:30 p.m. Eastern Time (ET) in New...
